Are These Stocks A Sure Bet? – Globalstar, Inc. (GSAT), iBio, Inc. (IBIO)

The shares of Globalstar, Inc. have decreased by more than -13.92% this year alone. The shares recently went down by -9.33% or -$0.14 and now trades at $1.36. The shares of iBio, Inc. (NYSE:IBIO), has slumped by -59.97% year to date as of 12/05/2017. The shares currently trade at $0.16 and have been able to report a change of -14.54% over the past one week.

The stock of Globalstar, Inc. and iBio, Inc. were two of the most active stocks on Tueday. Investors seem to be very interested in what happens to the stocks of these two companies but do investors favor one over the other? We will analyze the growth, profitability, risk, valuation, and insider trends of both companies and see which one investors prefer.

Profitability and Returns

Growth alone cannot be used to see if the company will be valuable. Shareholders will be the losers if a company invest in ventures that aren’t profitable enough to support upbeat growth. In order for us to accurately measure profitability and return, we will be using the EBITDA margin and Return on Investment (ROI), which balances the difference in capital structure. The ROI of GSAT is -7.70% while that of IBIO is -41.70%. These figures suggest that GSAT ventures generate a higher ROI than that of IBIO.

Cash Flow 

The value of a stock is ultimately determined by the amount of cash flow that the investors have available. Over the last 12 months, GSAT’s free cash flow per share is a positive 0.01, while that of IBIO is negative -0.89.

Liquidity and Financial Risk

The ability of a company to meet up with its short-term obligations and be able to clear its longer-term debts is measured using Liquidity and leverage ratios. The current ratio for GSAT is 0.30 and that of IBIO is 4.30. This implies that it is easier for GSAT to cover its immediate obligations over the next 12 months than IBIO. The debt ratio of GSAT is 2.85 compared to 2.84 for IBIO. GSAT can be able to settle its long-term debts and thus is a lower financial risk than IBIO.


GSAT currently trades at a P/B of 8.00, and a P/S of 15.71 while IBIO trades at a P/B of 1.58, and a P/S of 36.55. This means that looking at the earnings, book values and sales basis, GSAT is the cheaper one. It is very obvious that earnings are the most important factors to investors, thus analysts are most likely to place their bet on the P/E.

Analyst Price Targets and Opinions

The mistake some people make is that they think a cheap stock has more value to it. In order to know the value of a stock, there is need to compare its current price to its likely trading price in the future. The price of GSAT is currently at a -45.6% to its one-year price target of 2.50. Looking at its rival pricing, IBIO is at a -94.67% relative to its price target of 3.00. This figure implies that over the next one year, IBIO is a better investment.

When looking at the investment recommendation on say a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell), GSAT is given a 2.00.

Insider Activity and Investor Sentiment

Short interest or otherwise called the percentage of a stock’s tradable shares currently being shorted is another data that investors use to get a handle on sentiment. The short ratio for GSAT is 20.48 while that of IBIO is just 0.41. This means that analysts are more bullish on the forecast for IBIO stock.


The stock of Globalstar, Inc. defeats that of iBio, Inc. when the two are compared, with GSAT taking 5 out of the total factors that were been considered. GSAT happens to be more profitable, generates a higher ROI, has higher cash flow per share, higher liquidity and has a lower financial risk. When looking at the stock valuation, GSAT is the cheaper one on an earnings, book value and sales basis. Finally, the sentiment signal for GSAT is better on when it is viewed on short interest.

Previous ArticleNext Article

Related Post

Revisit the buy and-hold case for VASCO Data Secur... VASCO Data Security International, Inc. (NASDAQ:VDSI) fell by -8.30% in Friday’s trading session from $12.05 to $11.05 and has now fallen 4 consecutiv...
Drilling Down Into the Books for SCANA Corporation... SCANA Corporation (NYSE:SCG) is an interesting stock at present. Now trading with a market value of 10.34B, the company has a mix of catalysts and obs...
Geron Corporation (GERN) vs. Cara Therapeutics, In... Geron Corporation (NASDAQ:GERN) and Cara Therapeutics, Inc. (NASDAQ:CARA) are the two most active stocks in the Biotechnology industry based on today’...
Comparing Top Moving Stocks General Motors Company... The shares of General Motors Company have increased by more than 17.65% this year alone. The shares recently went down by -0.94% or -$0.39 and now tra...
Reliable Long-term Trend to Profit From: Amicus Th... The shares of Amicus Therapeutics, Inc. have decreased by more than -2.99% this year alone. The shares recently went down by -6.37% or -$0.95 and now ...